Literature DB >> 18761560

Immune responses in hepatitis C virus infection and mechanisms of hepatitis C virus persistence.

Kazumasa Hiroishi1, Takayoshi Ito, Michio Imawari.   

Abstract

Immune responses against hepatitis C virus (HCV) play a crucial role in the pathogenesis of chronic hepatitis C. HCV infection often persists and leads to chronic hepatitis and eventually cirrhosis. Accumulated data suggest that HCV proteins suppress host immune responses through the suppression of functions of immune cells, such as cytotoxic T lymphocytes, natural killer cells, and dendritic cells. They also suppress the type 1 interferon signaling system. The resulting insufficient immune responses against HCV lead to the sustained infection. The appropriate control of immune responses would contribute to the eradication of HCV and the improvement of hepatitis, but there are still many issues to be clarified. This review describes the scientific evidence to support these emerging concepts, and will touch on the implications for improving antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18761560     DOI: 10.1111/j.1440-1746.2008.05475.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  11 in total

Review 1.  Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population.

Authors:  S Ramia; N M Melhem; K Kreidieh
Journal:  Infection       Date:  2012-01-12       Impact factor: 3.553

2.  Dominating expression of negative regulatory factors downmodulates major histocompatibility complex Class-II expression on dendritic cells in chronic hepatitis C infection.

Authors:  Shallu Tomer; Yogesh K Chawla; Ajay Duseja; Sunil K Arora
Journal:  World J Gastroenterol       Date:  2016-06-14       Impact factor: 5.742

3.  Innate immunity and hepatitis C virus infection: a microarray's view.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Infect Agent Cancer       Date:  2012-03-26       Impact factor: 2.965

4.  IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection.

Authors:  J-Y Chen; C-Y Lin; C-M Wang; Y-T Lin; S-N Kuo; C-F Shiu; S-W Chang; J Wu; I-S Sheen
Journal:  Genes Immun       Date:  2011-02-24       Impact factor: 2.676

Review 5.  New Insights into IDO Biology in Bacterial and Viral Infections.

Authors:  Susanne V Schmidt; Joachim L Schultze
Journal:  Front Immunol       Date:  2014-08-11       Impact factor: 7.561

6.  Serum Cytokine of IL-10 and IL-12 in Chronic Liver Disease: The Immune and Inflammatory Response.

Authors:  Hoda Mohamed El-Emshaty; Wesam Ahmad Nasif; Ibrahim Eldsoky Mohamed
Journal:  Dis Markers       Date:  2015-12-10       Impact factor: 3.434

Review 7.  Hepatitis C Virus Infection: Host⁻Virus Interaction and Mechanisms of Viral Persistence.

Authors:  DeGaulle I Chigbu; Ronak Loonawat; Mohit Sehgal; Dip Patel; Pooja Jain
Journal:  Cells       Date:  2019-04-25       Impact factor: 6.600

8.  Hepatitis C Virus Infection Cycle-Specific MicroRNA Profiling Reveals Stage-Specific miR-4423-3p Targets RIG-I to Facilitate Infection.

Authors:  Xijing Qian; Bingan Wu; Chen Xu; Zhongtian Qi
Journal:  Front Cell Infect Microbiol       Date:  2022-03-24       Impact factor: 5.293

9.  Comparative Immunogenicity in Rabbits of the Polypeptides Encoded by the 5' Terminus of Hepatitis C Virus RNA.

Authors:  Irina Sominskaya; Juris Jansons; Anastasija Dovbenko; Natalia Petrakova; Ilva Lieknina; Marija Mihailova; Oleg Latyshev; Olesja Eliseeva; Irina Stahovska; Inara Akopjana; Ivars Petrovskis; Maria Isaguliants
Journal:  J Immunol Res       Date:  2015-11-02       Impact factor: 4.818

10.  CD4+ primary T cells expressing HCV-core protein upregulate Foxp3 and IL-10, suppressing CD4 and CD8 T cells.

Authors:  Cecilia Fernandez-Ponce; Margarita Dominguez-Villar; Enrique Aguado; Francisco Garcia-Cozar
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.